AI-generated summary
This protocol describes a planned randomized, double-blind trial testing blue light at 401 nm applied to the vulvovaginal region, alongside fluconazole, in women with recurrent vulvovaginal candidiasis. The authors state that the trial will compare outcomes such as Candida albicans absence and quality of life across three groups, but no results are reported yet.
- Participants
- 51
- Who or what was studied
- Women aged 18 to 40 years with recurrent vaginal candidiasis who are in a stable relationship
- Wavelengths
- 401 nm
- Limits stated in the abstract
- This is a study protocol, so no efficacy results are available, and the abstract does not report the trial's findings.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on link.springer.com.
Record from PubMed, a service of the National Library of Medicine.
How to read a trial: what to check before relying on this kind of research.
Terms in this paper: Reactive oxygen species, Primary outcome, Depression, Wavelength, Anxiety. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.